NCT00918749View on ClinicalTrials.gov

Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women

PHASE2CompletedINTERVENTIONAL
Enrollment

205

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Postmenopausal Osteoporosis
Interventions
DRUG

150 mg

150 mg immediate release (IRBB) risedronate tablet administered orally at least 30 minutes before breakfast.

DRUG

75 mg

75 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast

DRUG

100 mg

100 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast

Trial Locations (6)

32117

Research Site, Daytona Beach

33901

Research Site, Fort Myers

47711

Research Site, Evansville

75247

Research Site, Dallas

78727

Research Site, Austin

96821

Research Site, Honolulu

Sponsors

Lead Sponsor

Warner Chilcott
All Listed Sponsors
lead

Warner Chilcott

INDUSTRY

NCT00918749 - Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women | Biotech Hunter | Biotech Hunter